Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

10x Genomics (TXG) Other Non-Current Assets (2018 - 2025)

10x Genomics' Other Non-Current Assets history spans 8 years, with the latest figure at $2.9 million for Q4 2025.

  • For Q4 2025, Other Non-Current Assets changed N/A year-over-year to $2.9 million; the TTM value through Dec 2025 reached $2.9 million, changed N/A, while the annual FY2025 figure was $2.9 million, N/A changed from the prior year.
  • Other Non-Current Assets for Q4 2025 was $2.9 million at 10x Genomics, up from $1.9 million in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $61.0 million in Q4 2023 and bottomed at $1.9 million in Q3 2025.
  • The 5-year median for Other Non-Current Assets is $5.2 million (2024), against an average of $10.9 million.
  • The largest YoY upside for Other Non-Current Assets was 413.93% in 2021 against a maximum downside of 85.54% in 2021.
  • A 5-year view of Other Non-Current Assets shows it stood at $8.6 million in 2021, then crashed by 66.26% to $2.9 million in 2022, then soared by 2002.03% to $61.0 million in 2023, then plummeted by 91.96% to $4.9 million in 2024, then crashed by 40.59% to $2.9 million in 2025.
  • Per Business Quant, the three most recent readings for TXG's Other Non-Current Assets are $2.9 million (Q4 2025), $1.9 million (Q3 2025), and $2.7 million (Q2 2025).